Skip to content

Clinical study of Dachaihu Decoction on patients with AECOPD and the effect of NLRP3 inflammatory pathway

Clinical study of Dachaihu Decoction on patients with AECOPD and the effect of NLRP3 inflammatory pathway

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300072410
Enrollment
Unknown
Registered
2023-06-13
Start date
2023-07-01
Completion date
Unknown
Last updated
2023-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

AECOPD

Interventions

Treatment group:Basic treatment of Western Medicine (oxygen therapy, antibiotics, bronchodilators, expectorants, hormones, noninvasive ventilation) +Dachaihu decoction
Control group:Basic treatment of Western Medicine (oxygen therapy, antibiotics, bronchodilators, expectorants, hormones, noninvasive ventilation)

Sponsors

Chongqing traditional Chinese medicine hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1.Patients with age between 40 and 85 years old; 2.Meet the diagnostic criteria of western medicine of chronic obstructive pulmonary disease with acute exacerbation and lung function in grade I- III; 3.TCM dialectic is shaoyang and yangming type; 4.Patients who voluntarily submit to treatment, observation and various examinations; 5.Sign the relevant informed consent.

Exclusion criteria

Exclusion criteria: 1.Patients with active pulmonary tuberculosis, lung cancer and lung abscess; 2.Breastfeeding or pregnant women, persons who preparing to become pregnant; 3.Patients with mental illness, severe neurological dysfunction or other reasons can not cooperate with treatment; 4.Combined with severe cardiovascular and other non-respiratory diseases; 5.Patients with severe cerebrovascular diseases, diseases of the blood system, nervous system and malignant tumors; 6.Those who are allergic to this drug; 7.Join other researchers.

Design outcomes

Primary

MeasureTime frame
Lung signs (wheezing, phlegm);Modified British medical research council(mMRC);Chronic Obstructive Pulmonary Disease assessment(CAT);TCM syndrome score;Pulmonary function;

Secondary

MeasureTime frame
Arterial blood gas analysis;procalcitonin;NOD-like receptor thermal protein domain associated protein 3;interleukin 18;interleukin1ß;

Countries

China

Contacts

Public ContactTu yadan

Chongqing traditional Chinese medicine hospital

tuyadan@163.com+86 137 3299 1862

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026